Skip to main content

Table 2 Medications among patients

From: Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19 infection and vaccination

Medication

Group 1a (n = 90)

Group 2b (n = 47)

NSAIDsc, n (%)

1 (1)

0 (0)

GCSd, n (%)

5 (6)

0 (0)

csDMARDse

  

Hydroxychloroquine, n (%)

3 (3)

1 (2)

Sulfasalazine, n (%)

1 (1)

2 (4)

Methotrexat, n (%)

23 (25)

12 (26)

Leflunomide, n (%)

3 (3)

4 (9)

Mycophenolate mofetil, n (%)

5 (6)

3 (7)

Cyclosporine, n (%)

1 (1)

2 (4)

Azathioprine, n (%)

1 (1)

0 (0)

bDMARDsf

  

TNFα inhibitors, n (%)

37 (41)

19 (40)

IL-6 inhibitors, n (%)

2 (2)

2 (4)

IL-1 inhibitors, n (%)

3 (5)

1 (2)

Rituximab, n (%)

2 (2)

0 (0)

Abatacept, n (%)

2 (2)

0 (0)

Targeted synthetic DMARDsg

  

Baricitinib, n (%)

1 (1)

1 (2)

  1. a Group 1 – pARD after infection, b Group 2 – pARD after vaccination, c NSAIDs – nonsteroidal anti-inflammatory drugs,
  2. d GCS – glucocorticosteroids, e csDMARDs – conventional syntetic disease-modifying anti-rheumatic drugs
  3. f bDMARDs – biologic disease-modifying anti-rheumatic drugs, g Targeted synthetic DMARDs – targeted synthetic disease-modifying anti-rheumatic drugs
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096